Statins and new-onset atrial fibrillation in a cohort of patients with hypertension: Analysis of electronic health records, 2006-2015 by Alves Cabratosa, Lia et al.
RESEARCH ARTICLE
Statins and new-onset atrial fibrillation in a
cohort of patients with hypertension. Analysis
of electronic health records, 2006–2015
Lia Alves-Cabratosa1, Maria Garcı´a-Gil1, Marc Comas-Cufı´1, Anna Ponjoan1,2, Ruth Martı´-
Lluch1,3, Dı´dac Parramon1,4, Jordi Blanch1, Marc Elosua-Bayes1, Rafel Ramos1,2,4*
1 Vascular Health Research Group of Girona (ISV-Girona). Institut Universitari d’Investigacio´ en Atencio´
Primària Jordi Gol (IDIAP Jordi Gol), Girona, Catalonia, Spain, 2 Institut d’Investigacio´ Biomèdica de Girona
(IDIBGI), Dr. Josep Trueta University Hospital, Girona, Catalonia, Spain, 3 Translab Research Group.
Department of Medical Sciences, School of Medicine, University of Girona, Girona, Catalonia, Spain,
4 Primary Care Services, Girona. Catalan Institute of Health (ICS), Girona, Catalonia, Spain
* rramos.girona.ics@gencat.cat
Abstract
Hypertension is the most prevalent risk factor for new-onset atrial fibrillation (AF). But few
studies have addressed the effect of statins on the incidence of this arrhythmia in patients
with hypertension. This study aimed to evaluate the effect of statins on new-onset of this
arrhythmia in a hypertensive population, accounting for AF risk. Data from the Information
System for the Development of Research in Primary Care was used to recruit a retrospec-
tive cohort of55-year-old hypertensive individuals with no ischemic vascular disease, in
2006–2007, followed up through 2015. The effect of initiating statin treatment on new-onset
atrial fibrillation was assessed with Cox proportional hazards models adjusted by the pro-
pensity score of receiving statin treatment, in the overall study population and stratified by
AF risk. Of 100 276 included participants, 9814 initiated statin treatment. The AF incidence
per 1000 person-years (95% confidence interval) was 12.5 (12.3–12.8). Statin use associ-
ated with a significant (9%) reduction in AF incidence. Differences in absolute AF incidence
were higher in the highest AF risk subgroup, and the estimated number needed to treat to
avoid one case was 720. The relative effect was poor, similar across groups, and non-signif-
icant, as was the association of statins with adverse effects. We found a limited protective
effect of statins over new-onset AF in this hypertensive population with no ischemic vascular
disease. If there is no further indication, hypertensive patients would not benefit from statin
use solely for AF primary prevention.
Introduction
Atrial fibrillation (AF) conveys a huge social, medical, and economic burden because it is the
most common arrhythmia in clinical practice and it associates with quality of life detriment
[1], and with increased mortality and morbidity risk, mainly from stroke and heart failure [2–
5].
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Clinical management of AF is based on strategies for rhythm and rate control, as well as
thromboprophylaxis [2]. But this arrhythmia tends to worsen, leading to longer, more frequent
attacks, and becoming a chronic condition because current approaches are limited [6,7].
Therefore, research on prevention strategies is strongly encouraged, including the potential
protective effect of statins [8]. Beyond their lipid-lowering effect, statins have been hypothe-
sized to target the electrical and structural transformation that constitutes the substrate for AF,
atrial remodelling, without the concomitant pro-arrhythmic effect associated with the anti-
arrhythmic drugs [9].
The effect of statins on new-onset AF has been analysed in a variety of populations [2,7,10].
A metaanalysis that compared studies with long versus short follow-up found no benefit of
statins on atrial fibrillation in the trials with longer term follow-up [10]. But studies are scarce
in patients with hypertension, which is the most prevalent risk factor for new-onset AF. The
hypertensive population would have specific pathophysiological mechanisms [11], towards
which prevention of new-onset AF could be directed. Additionally, the evaluation of AF risk
could allow population stratification and aid in patient counselling [12–14]. Both the study of
patients with hypertension and AF risk assessment could be useful to target individuals requir-
ing intervention and tailor preventative approaches to tackle this arrhythmia [12,13,15].
The few studies that addressed the effect of statins on new-onset AF included people with
ischemic heart disease [16], and thus, with statins as prophylaxis [17]. We found no studies on
the association of statins with incident AF in the older hypertensive population without ische-
mic heart disease. Neither has the effect of statins on incident AF been analysed in the context
of individual risk for this rhythm disturbance.
We examined the association of statins with incident AF in a hypertensive population with-
out ischemic vascular disease, according to their risk of suffering this arrhythmia.
Methods
Data source
Data were obtained from the Information System for the Development of Research in Primary
Care (SIDIAPQ) [18] database, which is a subset of SIDIAP optimised for research. SIDIAP
contains longitudinal medical records of a representative sample of patients attended by gen-
eral practitioners (GPs) in Catalonia, and covers about 80% of the total of 7.5 million persons
of Catalonia, attended in the primary care practices managed by the Catalan Institute of Health
[18]. SIDIAP data include demographic information, coded clinical diagnoses using the
International Classification of Diseases 10th revision (ICD-10), specialist referrals, hospital dis-
charge information (ICD-9), laboratory tests, and treatments (drug prescriptions and corre-
sponding pharmacy invoicing data). Encoding of identifiers ensures confidentiality of the
information in the SIDIAP database. GPs follow regulated protocols on data recording, and
are externally assessed for its completeness and continuity. Those records that are accredited
to be accurate and complete over predefined data quality standards constitute SIDIAPQ [19],
with which the present study was carried out. SIDIAPQ contains anonymised information on
about 2 million patients, attended by 1365 GPs, yielding almost 20 million person-years for the
period 2006–2015 [19], and it has been widely used in previous epidemiological research [20–
24]. Ethics approval for research using SIDIAPQ data was obtained from the Ethics Committee
for Clinical Research IDIAP Jordi Gol (P14/052).
Study population
We included patients aged 55 years or older, with previous hypertension without target organ
involvement. Hypertension was defined with the codes I10 and I15 in ICD-10, 401 in ICD-9,
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or with any antihypertensive treatment (adrenergic beta-antagonists, diuretics, calcium chan-
nel blockers, agents acting on the renin-angiotensin system, or other antihypertensive drugs).
Exclusion criteria
Patients were excluded if they had a history of AF, other arrhythmias, ischemic vascular disease
(defined as ischemic heart disease, stroke, transient ischemic attack, or peripheral artery dis-
ease), any revascularization procedure, or a filled prescription for any of the following medica-
tions: antiarrhythmics (class I and III), selective calcium channel blockers with direct cardiac
effects, digitalis, nitrates, and vitamin K antagonists, as surrogates of the exclusion conditions.
We also excluded individuals without a score on MEDEA deprivation index [25].
To avoid frailty bias, we further excluded patients with cancer, dementia, plegia, who
received a transplanted organ, or who were institutionalised, in dialysis, or under treatment
for cardiac conditions (Anatomical Therapeutic Chemical Classification code C01) at baseline.
Patients who had been under statin treatment before the entry date were also excluded, to
avoid a potential indication bias.
Study design and length of follow-up
We carried out an historical cohort study from July 2006 through December 2015, to analyse
the effect of statin initiation on new-onset AF. Patients were defined as new-users if they had
purchased statins for the first time during the recruitment period (from July 2006 through
December 2007). New-users and non-users (controls) kept their status during follow-up,
resembling the intention-to-treat approach in randomised controlled trials. Entry date was the
day of the first statin purchase, for new-users who met inclusion criteria. Controls were
ascribed a randomised entry date based on the distribution of new-users entry dates; they were
excluded if inclusion criteria were no longer met at the ascribed entry date. Baseline period
was defined as 1 year previous to entry date. Censoring applied to transfer from SIDIAP, end
of study period, or death, whichever occurred first.
Exposure
Statin initiation was the main exposure. Patients were considered highly adherent to statin
treatment when their medication possession ratio (MPR) was70%, over 6 months.
Participants were stratified according to different risks of suffering new-onset AF, as fol-
lows: less than 2.5% of new-onset AF risk at 5 years,2.5 to<7.5%, and 7.5% [26]. The risk
level was determined with a validated 5-year risk function of new-onset AF, developed in this
hypertensive population without ischemic vascular disease (see Table A in S1 Appendix).
Outcomes
We defined new-onset AF with the first entry of the following codes: I48 (ICD-10), and 4273
and subcategories (ICD-9). We also examined the adverse effects of being a statin user. Liver
toxicity and myopathy were considered attributable to statins if they occurred within the first
year of treatment. Diabetes, hemorrhagic stroke, and malignant neoplasms were considered
attributable to statins if they occurred after one year of statin initiation: they were considered
more likely to be associated with long-term statin use [27].
Baseline covariates
The following covariates at baseline were considered potentially associated to statin treatment
and to the study outcome: age, sex, a deprivation index (developed for Spain by the MEDEA
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researchers[25]), height, weight, systolic and diastolic blood pressure (BP), smoking, glucose,
total cholesterol, high (HDL) and low (LDL) density lipoprotein cholesterol, obesity, dyslipi-
daemia, valvular heart disease, hypertension, diabetes, asthma, chronic obstructive pulmonary
disease, sleep apnoea, arthritis, hyperthyroidism, hypothyroidism, chronic kidney disease,
heart failure, treatments other than statins (non-statin lipid-lowering drugs, diuretics, beta
blocking agents, calcium-channel blockers, agents acting on the renin-angiotensin system,
other antihypertensives, antidiabetic drugs, corticosteroids for systemic use, anti-inflamma-
tory and antirrheumatic drugs, psycholeptics, psychoanaleptics), and coronary heart disease
risk according to the Framingham function adapted to the Spanish population, duly validated
and named the Framingham-REGICOR risk function [28].
Statistical methods
Continuous variables were expressed as mean (standard deviation) and categorical variables as
percentages. We used 10 multiple imputations by chained equations [29] to replace the miss-
ing baseline values of systolic and diastolic BP, pulse pressure, weight, height, body mass index
(BMI), glycaemia, total cholesterol, HDL and LDL cholesterol, and triglycerides. In sensitivity
analyses, we compared results restricted to the population with complete data and those
including imputed data (see Sensitivity Analyses in Tables C-E in S1 Appendix).
To avoid the selection bias associated with non-random treatment allocation, we derived a
logistic model based on variables that could potentially influence the odds of receiving statin
prescription, and obtained the propensity score (PS) of statin treatment for each study partici-
pant. Variables were considered well balanced if the standardised differences between new-
users and non-users were<0.10 after adjusting by PS.
We built Cox proportional hazard models to estimate the effect of being a new user on
new-onset AF, amongst all the population and within risk strata, adjusted by the PS of initiat-
ing statin treatment. In sensitivity analyses, we studied the subpopulation of patients with high
adherence to statin treatment.
We also estimated the adverse effects of being a new user of statins. We tested linearity of
the PS with respect to new-onset AF and the proportionality of hazards assumption. We also
calculated crude incidences and 1-year number needed to treat (NNT) to prevent one addi-
tional case of new-onset AF, or to contribute to one additional case of the adverse effects con-
sidered. Statistical significance was set at p<0.01.
All analyses were conducted using R-software [30] (version 3.0.1; R Foundation for Statisti-
cal Computing, Vienna, Austria), including MICE package for multiple imputation [31].
Results
Study population
From July 2006 through December 2015, SIDIAPQ recorded 163 442 eligible patients, of which
100 276 were included in the cohort and 9814 (9.8%) of these initiated statin treatment (Fig 1).
Median (1st-3rd quartile) MPR was 67% (33–100%), and 90% of new-users had high adherence
to treatment (6-month MPR70%). Median (1st-3rd quartiles) follow-up was 8.5 years (8.1–
8.9) (see Table B in S1 Appendix, which shows the follow-up by risk groups).
Table 1 displays the baseline characteristics of the study population, comparing new-users
with controls, before and after adjusting by PS. Before PS adjustment, new-users had worse
lipid profile, higher prevalence of diabetes, and slightly higher prevalences of comorbidities
and concomitant treatments. Standardised differences were<0.10 after adjusting by PS.
Missing data count and a comparison between the imputed and the complete case dataset are
shown in Tables C and D in S1 Appendix. Mean values of the imputed variables tended to be
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lower, as expected (see Table C in S1 Appendix). Overall, the population in the complete case
dataset had higher prevalence of diabetes and slightly higher prevalence of comorbidities and con-
comitant treatments; this pattern persisted after PS adjustment (Table D in S1 Appendix).
Overall, 9873 participants had a record of new-onset AF, a total crude incidence of 12.5 per
1000 person-years (95% confidence interval–CI-, 12.3–12.8). Table 2 shows the crude AF inci-
dence was higher in non-users of statins.
Effect of statins on AF incidence
Initiation of statin treatment associated with a significant reduction of AF incidence of 9%.
Sensitivity analysis of AF incidence in patients with MPR70% at 6 months showed a similar,
Fig 1. Study flowchart.
https://doi.org/10.1371/journal.pone.0186972.g001
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Table 1. Baseline characteristics of new-users and non-users of statins before and after propensity score adjustment.
Before PS adjustment After PS adjustment
Statin new-
users
(n = 90462)
Non-users
(n = 9814)
SDf Statin new-users
(n = 90462)
Non-users
(n = 9814)
SDf
Age, years 67.3 (8.1) 68.2 (8.9) 0.11 68.2 (8.0) 68.1 (8.8) -0.01
Men 39.0 40.2 0.02 39.6 40.1 0.01
MEDEA index
Rural areas 14.4 17.8 0.09 17.7 17.1 -0.02
Urban areas (quintile)
First 6.0 6.1 <0.01 5.9 6.1 0.01
Second 13.9 13.8 <0.01 13.5 13.8 0.01
Third 21.3 20.6 -0.02 20.4 20.7 0.01
Fourth 22.3 21.1 -0.03 21.1 21.3 <0.01
Fifth 22.0 20.6 -0.04 20.7 20.7 <0.01
Systolic BP, mmHg 138.5 (16.3) 137.6 (16.3) -0.05 137.9 (16.3) 137.7 (16.3) -0.01
Diastolic BP, mmHg 79.4 (9.5) 78.9 (9.5) -0.06 79.0 (9.5) 78.9 (9.5) -0.01
Pulse pressure 59.1 (14.4) 58.8 (14.6) -0.02 58.9 (14.4) 58.8 (14.6) -0.01
Weight, Kg 75.6 (13.4) 74.6 (13.4) -0.08 74.5 (13.4) 74.7 (13.4) 0.02
Height, cm 158.7 (8.9) 158.9 (9.1) 0.02 158.8 (8.9) 158.9 (9.1) 0.01
BMI, Kg/m2 30.0 (4.8) 29.5 (4.8) -0.10 29.5 (4.8) 29.5 (4.8) 0.01
Total cholesterol, mg/dl* 245.0 (40.5) 209.8 (32.6) -0.96 213.5 (22.9) 213.2 (20.3) -0.01
HDL-c, mg/dl 56.6 (14.0) 57.7 (14.2) 0.08 57.7 (14.0) 57.5 (14.2) -0.01
LDL-c, mg/dl 159.3 (36.2) 129.1 (28.8) -0.92 132.1 (22.4) 132.0 (18.6) -0.01
Triglycerides, mg/dl 145.8 (84.9) 115.2 (57.3) -0.42 120.7 (79.6) 118.0 (53.7) -0.04
Glucose, mg/dl 110.2 (34.8) 102.4 (26.4) -0.25 103.8 (34.1) 103.1 (25.9) -0.02
Alcohol consumption
None 93.4 95.0 0.07 93.9 95.0 0.05
Low-risk 6.0 4.5 -0.06 5.6 4.5 -0.05
High-risk 0.6 0.4 -0.03 0.5 0.4 -0.01
Smoking 19.5 17.9 -0.04 18.0 18.1 <0.01
Diabetes 22.3 13.8 -0.22 13.0 13.5 0.02
Arthritis 1.2 1.0 -0.02 1.0 1.0 <0.01
Hyperthyroidism 1.0 0.9 -0.01 0.9 0.9 <0.01
Hypothyroidism 5.5 4.5 -0.04 4.4 4.6 0.01
COPD 6.4 6.5 <0.01 6.6 6.5 <0.01
Asthma 4.2 4.1 <0.01 4.1 4.1 <0.01
Sleep apnoea 1.7 1.4 -0.03 1.3 1.4 <0.01
Chronic kidney disease 2.2 1.8 -0.03 1.8 1.8 <0.01
Valvular heart disease 1.8 1.6 -0.02 1.6 1.7 <0.01
Heart failure 0.9 0.9 <0.01 0.9 0.9 <0.01
Concomitant treatment
Diuretics 33.3 27.1 -0.13 26.8 27.5 0.02
Beta blockers 15.3 12.4 -0.09 12.1 12.5 0.01
Calcium channel
blockers*
13.0 9.7 -0.10 9.2 9.8 0.02
Agents acting on
renin-angiotensin
system
60.2 46.5 -0.28 45.5 48.0 0.05
Other
antihypertensives
4.1 3.4 -0.04 3.3 3.5 0.01
(Continued )
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although not significant, effect (HR 0.91; 95% CI 0.81–1.02). Table 2 shows the hazard ratios
(HRs) for statin new-users and the statin NNT of incident AF for the whole study population
Table 1. (Continued)
Before PS adjustment After PS adjustment
Statin new-
users
(n = 90462)
Non-users
(n = 9814)
SDf Statin new-users
(n = 90462)
Non-users
(n = 9814)
SDf
Hypoglycemic
Agents
17.8 9.0 -0.26 7.4 8.2 0.03
Lipid-lowering
drugs, non-statins
5.1 2.4 -0.15 1.9 2.1 0.02
AF risk subgroups
<2.5% 29.0 28.4 -0.01 28.0 28.5 0.01
2.5–7.5% 51.8 48.6 -0.06 50.0 48.8 -0.02
7.5% 19.2 23.0 0.09 21.7 22.6 0.02
Framingham-REGICOR risk † 6.7 (5.4) 5.2 (4.4) -0.31 5.5 (5.3) 5.3 (4.3) -0.05
Framingham-REGICOR <10% risk
(subgroups,%) ‡
AF risk <2.5% 88.4 96.3 0.30 96.6 96.9 0.02
AF risk2.5–7.5% 78.9 89.1 0.28 89.7 89.7 <0.01
AF risk7.5% 70.3 77.7 0.17 79.4 77.6 -0.04
Data are displayed as % or mean (SD).
* Selective calcium channel blockers with mainly vascular effects.
† Framingham-REGICOR coronary risk function [28].
‡Among those with a score <10% on the Framingham-REGICOR coronary risk function [28], % of participants within each AF risk subgroup.
BMI indicates body mass index; BP, blood pressure; COPD, chronic obstructive pulmonary disease; HDL, high density lipoprotein; LDL, low density
lipoprotein; MEDEA, socioeconomic deprivation index; N, number of cases; PS, propensity score of statin treatment; SD, standard deviation; SDf,
standardised differences.
https://doi.org/10.1371/journal.pone.0186972.t001
Table 2. Hazard ratios of statin use for incident atrial fibrillation and adverse effects of statins.
New-users Non-users
Events Incidence rate* (95% CI) Events Incidence rate* (95% CI) HR (95%CI) NNT+
AF, total population 834 10.6 (9.8–11.3) 9039 12.7 (12.5–13.0) 0.91 (0.84–0.99) 1366
AF risk group
<2.5% 75 3.1 (2.4–3.9) 785 3.6 (3.3–3.9) 0.91 (0.69–1.21) 5884‡
2.5 to <7.5% 420 10.1 (9.1–11.2) 4117 11.6 (11.3–12.0) 0.97 (0.86–1.08) 4590‡
7.5% 338 25.3 (22.5–28.1) 4137 29.6 (28.6–30.5) 0.93 (0.82–1.06) 720‡
Adverse effects
Cancer 1460 22.0 (20.8–23.1) 13463 22.4 (22.1–22.8) 1.03 (0.97–1.09) -
Hemorrhagic stroke 126 1.8 (1.5–2.1) 1373 2.1 (2.0–2.2) 0.84 (0.69–1.03) -
Diabetes 2094 34.6 (33.1–36.1) 15628 27.3 (26.9–27.7) 0.97 (0.92–1.02) -
Hepatotoxicity 8 0.8 (0.2–1.4) 57 0.6 (0.5–0.8) - -
Myopathy 3 - 23 0.3 (0.1–0.4) - -
*per 1000 person-year.
+at 1 year.
‡estimated.
AF indicates atrial fibrillation; CI confidence interval; HR hazard ratio; NNT, number needed to treat.
https://doi.org/10.1371/journal.pone.0186972.t002
Statins and primary prevention of atrial fibrillation in patients with hypertension
PLOS ONE | https://doi.org/10.1371/journal.pone.0186972 October 26, 2017 7 / 13
and for each risk-level subgroup. The association of statins with AF incidence did not differ by
risk subgroups, and the size effect was similar to that in the overall study population, although
non-significant. Similar results are displayed in analyses restricted to the complete case dataset
(see Table E in S1 Appendix). Table B in S1 Appendix shows predicted risk compared well
with observed risk within each 5-year risk-level subgroup.
Adverse effects of statins
We observed no significant association of statin initiation with its potential adverse effects
(Table 2). Similar results of analysis restricted to the complete case dataset are displayed in
Table E in S1 Appendix.
Discussion
Main findings
Statin initiation showed a minimal but significant association with lower AF incidence. The
absolute risk reduction increased with higher estimated risk, whereas the relative risk of this
arrhythmia was similar across risk stratification and did not reach statistical significance, prob-
ably because splitting the population into risk subgroups reduced statistical power. The 1-year
NNT for new-onset AF was too high to advocate the use of statins in primary prevention of
this arrhythmia, not even in the highest risk group. We found no association of statins with
the studied adverse effects.
Previous studies
Statins reduced the risk of new-onset AF less than what has been reported for other outcomes,
such as secondary prevention of ischemic heart disease [32]. The 2014 AHA guidelines on AF
reported no benefit of statins in primary prevention of this arrhythmia in patients without car-
diovascular disease [7], and the latest ESC guidelines stated the lack of effect of statins in any
setting [2,10].
With regard to patients with hypertension, the meta-analysis cited in these ESC guidelines
[10] included two studies that involved patients with this condition and found no effect of stat-
ins on incident AF. In conflict with these results, statin treatment has been associated with a
19% decrease of AF risk in patients65 years old [16]. The decrease in AF risk was smaller in
our analysis, perhaps due to differences in the studied populations. Hung et al. [16] reported
that statin therapy was not as beneficial in patients without other cardiovascular comorbidities.
We specifically excluded the population that might be taking statins for prevention of ischemic
heart disease, defined as persons with history of ischemic heart disease, stroke, transient ische-
mic attack, and peripheral artery disease [17]. These exclusion criteria may imply higher risk
of AF, and therefore our study population could be considered at lower risk of new-onset AF.
Statin adverse effects
No excess of severe adverse effects related to statin initiation was found during follow-up.
Increased incidence of diabetes associated with statin treatment has been evidenced in a meta-
analysis of randomised controlled trials, although no statistical significance was shown in
patients with hypertension [33], in accordance with our results. Diabetes [34], myopathy [35]
and hepatopathy [36] are more frequent in intensive statin treatment regimes, and 88% of per-
sons treated with statins were in low-moderate potency regimes in our study. In agreement
with previous reports [37,38], we found no increased risk of cancer or hemorrhagic stroke
associated with statin initiation. Still, we cannot exclude the possibility that incidence of
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diabetes, cancer, or haemorrhagic stroke might have increased in this population with longer
statin exposure.
Study characteristics and limitations
We focused on the study of a specific population of interest at increased risk of AF, i.e., hyper-
tensive individuals with no ischemic heart disease, in response to the request for research on
personalising the approach of patients at risk of this arrhythmia [2,13,39,40]. We had access to
SIDIAPQ, a large, anonymised, high-quality dataset that includes a considerable number of
participants with new-onset AF. Electronic medical records provide the opportunity to address
certain questions related to the effect of medical treatments. They contain data on individuals
often excluded from clinical trials (e.g. women, persons with diabetes), and thus reflect ‘real-
world’ practice, at a reasonable cost [41], and there is evidence of a correspondence between
studies based on electronic medical records and randomised controlled trials [42].
At the same time, the peril of biased results has been suggested for observational studies,
unless some key points are addressed [43]. Concerning statins effects, study populations must
be comparable such that they differ only in their statin use. Thus, in addition to using a new–
users design (as opposed to prevalent users) we adjusted statin use by the propensity score
(PS) for this treatment to prevent indication bias, and randomly allocated the index dates of
statin non-users following the distribution of new-users to prevent immortality bias[44]. We
also applied sample restriction, excluding patients with cancer, dementia, plegia, transplanted,
institutionalized, or in dialysis, to reduce the healthy user bias [45, 46]. However, some unmea-
sured factors may influence prescription patterns and treatment adherence, including unre-
ported side effects, frequency of access to medical care, and patient willingness to take the drug
[47].
To avoid the selection bias associated with missing values, we replaced those of the continu-
ous variables, instead of excluding these records. Individuals with missing values had a slightly
healthier profile, and the process of multiple imputation was intended to account for this. The
characteristics of the study population met plausibility criteria for the missing-at-random
assumption for all imputed variables except the MEDEA deprivation index. Its missing mecha-
nism was completely at random, thus exclusion of participants who lacked a MEDEA score
did not imply selection bias.
We could not distinguish between various types of AF because we used ICD codes to iden-
tify the diagnosis. Similarly, we could not differentiate AF from atrial flutter, because they
share the same ICD code. Underrecording of AF also could not be excluded, but if it occurred,
it would have been randomly distributed among new-users and non-users, and any potential
bias would have tended towards the null. Finally, underrecording of moderate myopathy and
hepatopathy could partially explain the lack of association of these adverse effects with statins,
since their low incidence hindered accurate estimation of their association with statin use.
Conclusions
Statin initiation showed a statistically significant 9% reduction of new-onset AF that was not
clinically relevant, as evidenced by a high 1-year NNT. Even in the highest risk group, the
absolute risk reduction was too small to support the use of statins solely for primary prevention
of incident AF. Furthermore, their adverse effects could not be unreservedly dismissed.
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